Abstract

Background: Diabetic neuropathy is a common complication in diabetes, with patients typically experiencing diverse sensory symptoms including dysesthesias in the feet and usually accompanied by sleep disturbance. There is still no comprehensive understanding of the underlying biologic processes responsible for diabetic neuropathic pain. Thus, the current symptomatic therapy remains unsatisfactory. Recent experimental evidence suggests that botulinum toxin type A (BoNT/A) may not only inhibit the release of acetylcholine at the neuromuscular junctions, but also modulate afferent sensory fiber firing, thereby relieving neuropathic pain. Methods: A double-blind crossover trial of intradermal BoNT/A for diabetic neuropathic pain in 18 patients was conducted to evaluate the effectiveness. Results: We find significant reduction in visual analog scale (VAS) of pain by 0.83 ± 1.11 at 1 week, 2.22 ± 2.24 at 4 weeks, 2.33 ± 2.56 at 8 weeks, and 2.53 ± 2.48 at 12 weeks after injection in the BoNT/A group, as compared to the respective findings for a placebo group of 0.39 ± 1.18, -0.11 ± 2.04, 0.42 ± 1.62, and 0.53 ± 1.57 at the same timepoints (p <0.05). Within the BoNT/A group, 44.4% of the participants experienced a reduction of VAS ≥3 within 3 months after injection, whereas there was no similar response in the placebo group. At the 4-week postinjection stage, improvement in sleep quality was measured using the Chinese version of the Pittsburgh Sleep Quality Index. Conclusions: This pilot study found that botulinum toxin type A significantly reduced diabetic neuropathic pain and transiently improved sleep quality. Further large-scaled study is warranted.

Original languageEnglish
Pages (from-to)1473-1478
Number of pages6
JournalNeurology
Volume72
Issue number17
DOIs
Publication statusPublished - Apr 28 2009

Fingerprint

Type A Botulinum Toxins
Botulinum Toxins
Neuralgia
Cross-Over Studies
Sleep
Placebos
Injections
Diabetic Neuropathies
Paresthesia
Neuromuscular Junction
Pain Measurement
Diabetes Complications
Visual Analog Scale
Double-Blind Method
Acetylcholine
Foot

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Botulinum toxin for diabetic neuropathic pain : A randomized double-blind crossover trial. / Yuan, Rey-Yue; Sheu, Jau-Jiuan; Yu, Jia Ming; Chen, Wei Ta; Tseng, Ing Jy; Chang, Hsiu Hui; Hu, Chaur-Jong.

In: Neurology, Vol. 72, No. 17, 28.04.2009, p. 1473-1478.

Research output: Contribution to journalArticle

@article{ae344c90c5c04a56a69f03c6807cc1fb,
title = "Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial",
abstract = "Background: Diabetic neuropathy is a common complication in diabetes, with patients typically experiencing diverse sensory symptoms including dysesthesias in the feet and usually accompanied by sleep disturbance. There is still no comprehensive understanding of the underlying biologic processes responsible for diabetic neuropathic pain. Thus, the current symptomatic therapy remains unsatisfactory. Recent experimental evidence suggests that botulinum toxin type A (BoNT/A) may not only inhibit the release of acetylcholine at the neuromuscular junctions, but also modulate afferent sensory fiber firing, thereby relieving neuropathic pain. Methods: A double-blind crossover trial of intradermal BoNT/A for diabetic neuropathic pain in 18 patients was conducted to evaluate the effectiveness. Results: We find significant reduction in visual analog scale (VAS) of pain by 0.83 ± 1.11 at 1 week, 2.22 ± 2.24 at 4 weeks, 2.33 ± 2.56 at 8 weeks, and 2.53 ± 2.48 at 12 weeks after injection in the BoNT/A group, as compared to the respective findings for a placebo group of 0.39 ± 1.18, -0.11 ± 2.04, 0.42 ± 1.62, and 0.53 ± 1.57 at the same timepoints (p <0.05). Within the BoNT/A group, 44.4{\%} of the participants experienced a reduction of VAS ≥3 within 3 months after injection, whereas there was no similar response in the placebo group. At the 4-week postinjection stage, improvement in sleep quality was measured using the Chinese version of the Pittsburgh Sleep Quality Index. Conclusions: This pilot study found that botulinum toxin type A significantly reduced diabetic neuropathic pain and transiently improved sleep quality. Further large-scaled study is warranted.",
author = "Rey-Yue Yuan and Jau-Jiuan Sheu and Yu, {Jia Ming} and Chen, {Wei Ta} and Tseng, {Ing Jy} and Chang, {Hsiu Hui} and Chaur-Jong Hu",
year = "2009",
month = "4",
day = "28",
doi = "10.1212/01.wnl.0000345968.05959.cf",
language = "English",
volume = "72",
pages = "1473--1478",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "17",

}

TY - JOUR

T1 - Botulinum toxin for diabetic neuropathic pain

T2 - A randomized double-blind crossover trial

AU - Yuan, Rey-Yue

AU - Sheu, Jau-Jiuan

AU - Yu, Jia Ming

AU - Chen, Wei Ta

AU - Tseng, Ing Jy

AU - Chang, Hsiu Hui

AU - Hu, Chaur-Jong

PY - 2009/4/28

Y1 - 2009/4/28

N2 - Background: Diabetic neuropathy is a common complication in diabetes, with patients typically experiencing diverse sensory symptoms including dysesthesias in the feet and usually accompanied by sleep disturbance. There is still no comprehensive understanding of the underlying biologic processes responsible for diabetic neuropathic pain. Thus, the current symptomatic therapy remains unsatisfactory. Recent experimental evidence suggests that botulinum toxin type A (BoNT/A) may not only inhibit the release of acetylcholine at the neuromuscular junctions, but also modulate afferent sensory fiber firing, thereby relieving neuropathic pain. Methods: A double-blind crossover trial of intradermal BoNT/A for diabetic neuropathic pain in 18 patients was conducted to evaluate the effectiveness. Results: We find significant reduction in visual analog scale (VAS) of pain by 0.83 ± 1.11 at 1 week, 2.22 ± 2.24 at 4 weeks, 2.33 ± 2.56 at 8 weeks, and 2.53 ± 2.48 at 12 weeks after injection in the BoNT/A group, as compared to the respective findings for a placebo group of 0.39 ± 1.18, -0.11 ± 2.04, 0.42 ± 1.62, and 0.53 ± 1.57 at the same timepoints (p <0.05). Within the BoNT/A group, 44.4% of the participants experienced a reduction of VAS ≥3 within 3 months after injection, whereas there was no similar response in the placebo group. At the 4-week postinjection stage, improvement in sleep quality was measured using the Chinese version of the Pittsburgh Sleep Quality Index. Conclusions: This pilot study found that botulinum toxin type A significantly reduced diabetic neuropathic pain and transiently improved sleep quality. Further large-scaled study is warranted.

AB - Background: Diabetic neuropathy is a common complication in diabetes, with patients typically experiencing diverse sensory symptoms including dysesthesias in the feet and usually accompanied by sleep disturbance. There is still no comprehensive understanding of the underlying biologic processes responsible for diabetic neuropathic pain. Thus, the current symptomatic therapy remains unsatisfactory. Recent experimental evidence suggests that botulinum toxin type A (BoNT/A) may not only inhibit the release of acetylcholine at the neuromuscular junctions, but also modulate afferent sensory fiber firing, thereby relieving neuropathic pain. Methods: A double-blind crossover trial of intradermal BoNT/A for diabetic neuropathic pain in 18 patients was conducted to evaluate the effectiveness. Results: We find significant reduction in visual analog scale (VAS) of pain by 0.83 ± 1.11 at 1 week, 2.22 ± 2.24 at 4 weeks, 2.33 ± 2.56 at 8 weeks, and 2.53 ± 2.48 at 12 weeks after injection in the BoNT/A group, as compared to the respective findings for a placebo group of 0.39 ± 1.18, -0.11 ± 2.04, 0.42 ± 1.62, and 0.53 ± 1.57 at the same timepoints (p <0.05). Within the BoNT/A group, 44.4% of the participants experienced a reduction of VAS ≥3 within 3 months after injection, whereas there was no similar response in the placebo group. At the 4-week postinjection stage, improvement in sleep quality was measured using the Chinese version of the Pittsburgh Sleep Quality Index. Conclusions: This pilot study found that botulinum toxin type A significantly reduced diabetic neuropathic pain and transiently improved sleep quality. Further large-scaled study is warranted.

UR - http://www.scopus.com/inward/record.url?scp=67549127798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549127798&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000345968.05959.cf

DO - 10.1212/01.wnl.0000345968.05959.cf

M3 - Article

C2 - 19246421

AN - SCOPUS:67549127798

VL - 72

SP - 1473

EP - 1478

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 17

ER -